Literature DB >> 22006870

Psychometric characteristics of outcome measures in juvenile idiopathic arthritis: a systematic review.

Heather A van Mater1, John W Williams, Remy R Coeytaux, Gillian D Sanders, Alex R Kemper.   

Abstract

OBJECTIVE: To review the performance characteristics of the instruments most commonly used to measure clinical outcomes in juvenile idiopathic arthritis (JIA), including global assessments, articular indices, functional/disability assessments, and quality of life measures.
METHODS: As part of an Agency for Healthcare Research and Quality comparative effectiveness review of antirheumatic drugs, we explored the characteristics of commonly used outcome measures for JIA. English-language studies of children with JIA were identified from Medline and Embase. Two independent reviewers screened titles and abstracts, with subsequent full-text review of studies selected based on predetermined criteria.
RESULTS: We included 35 publications describing 34 unique studies and involving 14,831 patients. The Childhood Health Assessment Questionnaire (C-HAQ) was the most extensively studied instrument and had high reliability, but only moderate correlations with other indices of disease activity and poor responsiveness to change in disease status. The physician global assessment of disease activity (PGA) and articular indices had the strongest association with disease activity and were the most responsive to change. Measures of psychosocial function and quality of life were moderately associated with measures of disease activity, but were less responsive to changes in disease status.
CONCLUSION: In children with JIA, no single instrument was superior in reliability or validity or in describing the impact of JIA. Although the C-HAQ has been extensively evaluated, the PGA and articular indices appear to have the highest responsiveness to change and, therefore, the highest potential for detecting important differences in treatment response.
Copyright © 2012 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2012        PMID: 22006870     DOI: 10.1002/acr.20667

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  5 in total

Review 1.  Disease activity measures in paediatric rheumatic diseases.

Authors:  Nadia J Luca; Brian M Feldman
Journal:  Int J Rheumatol       Date:  2013-09-08

2.  Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial).

Authors:  Marloes Stam; Renske I Wadman; Camiel A Wijngaarde; Bart Bartels; Fay-Lynn Asselman; Louise A M Otto; H Stephan Goedee; Laura E Habets; Janke F de Groot; Marja A G C Schoenmakers; Inge Cuppen; Leonard H van den Berg; W Ludo van der Pol
Journal:  BMJ Open       Date:  2018-07-30       Impact factor: 2.692

3.  Juvenile idiopathic arthritis managed in the new millennium: one year outcomes of an inception cohort of Australian children.

Authors:  Georgina Tiller; Joanne Buckle; Roger Allen; Jane Munro; Peter Gowdie; Angela Cox; Jonathan Akikusa
Journal:  Pediatr Rheumatol Online J       Date:  2018-11-09       Impact factor: 3.054

4.  Assessment of fatigability in patients with spinal muscular atrophy: development and content validity of a set of endurance tests.

Authors:  Bart Bartels; Laura E Habets; Marloes Stam; Renske I Wadman; Camiel A Wijngaarde; Marja A G C Schoenmakers; Tim Takken; Erik H J Hulzebos; W Ludo van der Pol; Janke F de Groot
Journal:  BMC Neurol       Date:  2019-02-09       Impact factor: 2.474

5.  Patient-reported wellbeing and clinical disease measures over time captured by multivariate trajectories of disease activity in individuals with juvenile idiopathic arthritis in the UK: a multicentre prospective longitudinal study.

Authors:  Stephanie J W Shoop-Worrall; Kimme L Hyrich; Lucy R Wedderburn; Wendy Thomson; Nophar Geifman
Journal:  Lancet Rheumatol       Date:  2020-12-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.